Lung Disease & Respiratory Disorders

Lung Disease & Respiratory Disorders

Accelerate Your Drug Development Pipeline with Anilocus

Introducing AniLocus, your new partner in the world of respiratory drug development. With our in vivo preclinical CRO services, we aim to revolutionize in vivo assessments of therapeutics for lung diseases. As a growing contract research organization (CRO), we understand the complexity of respiratory diseases like Cystic Fibrosis, COPD, asthma, lung infections, and lung cancer. Our team is dedicated to providing innovative preclinical solutions for your pharmaceutical research needs. From translational disease models of respiratory infections and disorders to assessing device biocompatibility, we have you covered. Join us in the fight against lung disease and let our professional services support your groundbreaking medical advancements. Choose AniLocus for unparalleled preclinical support. Together, we can make a difference.

Contact Us! Learn more about our in vivo solutions:

Anilocus employee using an iPad in the laboratory. Our scientists are dedicated to excellent preclinical assessments of lung disease drug products and devices.

At Anilocus, we strive to offer quality, safety, and credibility to support your research efforts in the drug development process.

We offer preclinical solutions for respiratory drugs and therapy devices for multiple disease indications:

  • Acute Respiratory Distress Syndrome (ARDS)
  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Congenital Lung Disease
  • Hyperoxia/Hypoxia
  • Infectious Lung Disease
  • Inflammatory Lung Diseases
  • Influenza
  • Interstitial Lung Disease
  • Lung Cancer
  • Mesenchymal Stem Cell Therapy
  • Obstructive Sleep Apnea (OSA)
  • Pneumonia
  • Pulmonary Fibrosis
  • Respiratory Function Assessment
  • Tuberculosis (TB)

Our team supports your research efforts and offers unique animal models to assess therapies for rare lung diseases:

  • Alpha-1 Antitrypsin Deficiency (Alpha-1)
  • Birt-Hogg-Dubé Syndrome (BHD)
  • Cystic Fibrosis
  • Diffuse Idiopathic Pulmonary
  • Neuroendocrine Cell Hyperplasia (DIPNECH)
  • GLA/lymphangiomatosis
  • Hermansky-Pudlak Syndrome (HPS)
  • Lymphangioleiomyomatosis (LAM)
  • Pulmonary Alveolar Microlithiasis (PAM)
  • Pulmonary Alveolar Proteinosis (PAP)
  • Pulmonary Langerhans Cell Histiocytosis (PLCH)
Team Anilocus - Preclinical contract research organization (CRO) based in San Diego, California | In vivo research services

Our Team

What we offer:

Multiple animal models are used to assess lung disease drug development including:

  • Gene knockout/knockin/trapped
  • Transgenic rodents
  • Chemically-Induced Point Mutation rodents
  • Stress-induced models
  • Drug-Induced models
  • Metabolically-induced models (Diet-induced, Metabolic disorder, micronutrient deficient)
  • And more…

We conduct translational animal studies (in vivo and in vitro) collecting detailed, comprehensive results with rapid turnaround.

Drug modalities are different types of therapeutic agents. Each drug is a customizable tool designed for therapeutic intervention. The question is…does your product work and is it safe?

At AniLocus, we conduct relevant preclinical studies to assess any drug modality:

  • Antibodies (nanobodies, monoclonal)
  • Gene therapy (CRISPR, TALEN)
  • Viral therapy (adenovirus-AAV, lentivirus)
  • Oligo- and polypeptides (e.g., stapled and modified peptides)
  • Oligo- and polynucleotides (e.g., siRNAs, mRNAs, aptamers)
  • Polyglycosides
  • Macrocyclic molecules
  • Drug conjugates (e.g., antibody–drug conjugates, drug–drug conjugates, fluorescence-labeled drugs)
  • Targeted protein degraders (e.g., proteolysis-targeting chimeras (PROTACs) and molecular glues) that induce a chemical knockdown of proteins
  • Cellular therapies (stem cells, allogenic, autologous)

Using animal and human cells and tissue we can perform multiple interrogative assays depending on therapeutic area and sample type:

  • DNA: Extraction, PCR, ddPCR, qPCR, sequencing, genotyping
  • RNA: Gene expression profiling, RT-PCR, miRNA, Next-generation sequencing (Nanostring, Illumina), spatial transcriptomics, In situ hybridization (ISH), Multiplex ISH
  • Protein: Immunoassays (ELISA, EIA, Luminex), proteomics, ligand binding assays, protein expression, immunohistochemistry (IHC), immunocytochemistry (ICC), and  immunofluorescence (IF)
  • And more!
  1. White, E. S., Thomas, M., Stowasser, S., & Tetzlaff, K. (2022). Challenges for Clinical Drug Development in Pulmonary Fibrosis. Frontiers in pharmacology, 13, 823085. < https://doi.org/10.3389/fphar.2022.823085 >.
  2. GBD Chronic Respiratory Disease Collaborators (2020). Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. Respiratory medicine, 8(6), 585–596. < https://doi.org/10.1016/S2213-2600(20)30105-3 >.
  3. GBD 2016 Occupational Chronic Respiratory Risk Factors Collaborators, & GBD 2016 occupational chronic respiratory risk factors collaborators (2020). Global and regional burden of chronic respiratory disease in 2016 arising from non-infectious airborne occupational exposures: a systematic analysis for the Global Burden of Disease Study 2016. Occupational and environmental medicine, 77(3), 142–150. < https://doi.org/10.1136/oemed-2019-106013 >.
  4. Viegi, G., Maio, S., Fasola, S., & Baldacci, S. (2020). Global Burden of Chronic Respiratory Diseases. Journal of aerosol medicine and pulmonary drug delivery, 33(4), 171–177. < https://doi.org/10.1089/jamp.2019.1576 >.
  5. Hedner, J., & Zou, D. (2022). New pharmacologic agents for obstructive sleep apnoea: what do we know and what can we expect?. Current opinion in pulmonary medicine, 28(6), 522–528. < https://doi.org/10.1097/MCP.0000000000000920 >.